ReviewJournal of the National Medical Association2004
Diabetic nephropathy--a review of the natural history, burden, risk factors and treatment.
Review in Journal of the National Medical Association, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Performance of prediction models for nephropathy in people with type 2 diabetes: systematic review and external validation study.BMJ (Clinical research ed.) · 2021Pooled it
- Effect of bilirubin concentration on the risk of diabetic complications: A meta-analysis of epidemiologic studies.Scientific reports · 2017Pooled it
- A systematic literature review of sport and physical activity participation in culturally and linguistically diverse (CALD) migrant populations.Journal of immigrant and minority health · 2014Pooled it
- SOD2 gene Val16Ala polymorphism is associated with macroalbuminuria in Mexican type 2 diabetes patients: a comparative study and meta-analysis.BMC medical genetics · 2013Pooled it
- The association between the PPARγ2 Pro12Ala polymorphism and nephropathy susceptibility in type 2 diabetes: a meta-analysis based on 9,176 subjects.Diagnostic pathology · 2013Pooled it
- Clinical Validation of Type 1 Diabetes Coding in Hospital Discharge Records Using ADA Criteria: Implications for Spanish and European Health Data Spaces.Journal of clinical medicine · 2026Article
- Cepharanthine improves blood glucose levels and mitigates renal injury in streptozotocin-induced diabetic rats via restoring pancreatic β-cell integrity and reducing inflammation.Frontiers in pharmacology · 2026Article
- Association Between Blood Lead Levels and Diabetic Kidney Disease: A Cross-sectional Analysis of NHANES Data (1999-2018).Current molecular medicine · 2026Article
- Identification and validation of epithelial‑mesenchymal transition‑related genes for diabetic nephropathy by WGCNA and machine learning.Molecular medicine reports · 2025Article
- Correlation of Triglyceride-Glucose Index and the Presence of Microvascular Complications of Diabetes.Cureus · 2025Article
- Evaluating Feature Selection Methods for Accurate Diagnosis of Diabetic Kidney Disease.Biomedicines · 2024Article
- Risk factors for rapid kidney function decline in diabetes patients.Renal failure · 2024Review
- Sanziguben polysaccharides improve diabetic nephropathy in mice by regulating gut microbiota to inhibit the TLR4/NF-κB/NLRP3 signalling pathway.Pharmaceutical biology · 2023Article
- Determinants and Stratification of Microvascular Complications of Type 2 Diabetes Mellitus.Cureus · 2023Article
- High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023Article
- Machine-learning algorithm-based prediction of a diagnostic model based on oxidative stress-related genes involved in immune infiltration in diabetic nephropathy patients.Frontiers in immunology · 2023Article
- Association of Apolipoprotein E Gene Polymorphism with Type 2 Diabetic Nephropathy in the Southern Chinese Population.International journal of general medicine · 2023Article
- Predictors of cardio-kidney complications and treatment failure in patients with chronic kidney disease and type 2 diabetes treated with SGLT2 inhibitors.BMC medicine · 2022Article
- Epidemiological characteristics of diabetic kidney disease in Taiwan.Journal of diabetes investigation · 2021Review
- Role of Oxidative Stress and Reduced Endogenous Hydrogen Sulfide in Diabetic Nephropathy.Drug design, development and therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The earliest clinical evidence of diabetic nephropathy is microalbuminuria. Progression from microalbuminuria to overt nephropathy occurs in 20-40% within a 10-year period with approximately 20% of these patients progressing to end-stage renal disease. End-stage renal disease develops in 50% of type-1 diabetes patients with overt nephropathy within 10 years and in more than 75% by 20 years in the absence of treatment. In type-2 diabetes, a greater proportion of patients have microalbuminuria and overt nephropathy at or shortly after diagnosis of diabetes. The incidence of diabetes is increasing worldwide, with subsequent increase in the incidence of diabetic nephropathy. The risk factors identified in the development of DN from longitudinal and cross-sectional studies include race, genetic susceptibility, hypertension, hyperglycemia, hyperfiltration, smoking, advanced age, male sex, and high-protein diet. Treatment interventions in diabetic nephropathy include glycemic control, treatment of hypertension, hyperlipidemia, cessation of smoking, protein restriction, and renal replacement therapy. Multifactorial approach includes combined therapy targeting hyperglycemia, hypertension, microalbuminuria, and dyslipidemia.
Indexed as
Identifiers
15586648PMC2568593What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.